Patients with atherosclerotic cardiovascular disease receiving high-intensity statins have a lower risk of death than those on a lower intensity dose, according to new research published in JAMA Cardiology today.
The research, led by researchers at Stamford University, studied more than 500,000 patients aged between 21 and 84 years, looking into the relationship between the intensity of statin therapy and one-year cardiovascular mortality.
The study found that after one year mortality rates for those on different statin intensities were as follows: 4 percent for those receiving high-intensity statin therapy, 4.8 percent for those receiving moderate-intensity statin therapy, 5.7 percent for those receiving low-intensity statin therapy, and 6.6 percent for those receiving no statin therapy.
Professor Jeremy Pearson, Associate Medical Director at the British Heart Foundation, said:
“Heart disease is incurable – we have no way to reverse the furring of the arteries that can lead to a deadly heart attack or stroke. But decades of research, much of it funded by the BHF, show that statins can help save lives by slowing the progression of the disease.
“This large study showed that more intensive statin treatment reduced death rates further than low-intensity or no treatment in people with cardiovascular disease.
“While this research confirms the greater benefit of more intensive treatment, decisions on dosage require conversations between patients and their doctors.”
We currently fund around £100 million of new research into heart and circulatory disease each year and we are the largest independent funder of cardiovascular research in the UK and Europe. The BHF relies entirely on the generosity of its supporters to fund even more life saving research.
FIND OUT MORE ABOUT STATIN THERAPY